Advancing Tetraspecific T-Cell Engagers to the Clinic: Integrating CD3xCD28 Co-Stimulation Within Next-Generation Multispecific Formats
- Leveraging a modular platform capable of incorporating multiple specificities (up to tetraspecific and beyond) to enhance precision targeting and overcome current TCE limitations
- Exploring the integration of CD3 and CD28 within one engager to drive improved T-cell activation, persistence, and therapeutic efficacy versus traditional approaches
- Sharing the journey into first-in-human development of a tetraspecific engager, including design rationale, pathway to Phase I, and key considerations for safety and clinical advancement